March 17, 2026

NeuroSense announces that results from the PARADIGM Phase 2b clinical trial of PrimeC in ALS have been published in the prestigious journal JAMA Neurology.

The article presents an integrated analysis of PrimeC’s safety profile, clinical outcomes, and biomarker findings over 18 months in people with ALS.

The publication highlights consistent findings across multiple domains, including:

• Slower functional decline
• Reduced risk of ALS-related complications
• Modulation of disease-relevant biomarkers, including iron-regulatory and microRNA pathways

Together, these findings strengthen the scientific rationale for PrimeC’s potential as a disease-modifying therapy.

NeuroSense is grateful to the patients, investigators, and collaborators who made this work possible, and honored to partner with leading ALS research centers and their distinguished clinical teams in advancing research for people with ALS.

Read the full publication here.

Source: NeuroSense press release

European organization for Professionals and People with ALS (EUpALS) ivzw

Registered office: Vaartkom 17, B-3000 Leuven, Belgium

VAT: BE 0684.923.631 – Commercial Tribunal of Leuven

Tel: +32 (0)16-23 95 82     –  info@ALS.eu  –  www.ALS.eu